|
Patent landscape, scope, and claims: |
Patent Analysis: US 10,703,763 - A Novel Method for Treating Atopic Dermatitis
United States Patent 10,703,763, granted on July 7, 2020, details a method for treating atopic dermatitis. The patent claims focus on the use of specific Janus kinase (JAK) inhibitors for therapeutic application. The patent landscape surrounding this claim involves established players in the dermatology and immunology sectors, with a particular emphasis on JAK inhibitor development.
What is the Primary Therapeutic Indication Covered by US 10,703,763?
The core of patent US 10,703,763 is directed towards the treatment of atopic dermatitis, also known as eczema. The patent describes a method of administering a JAK inhibitor to a subject in need of such treatment. Atopic dermatitis is a chronic inflammatory skin condition characterized by pruritus, erythema, and skin lesions.
What Specific Compound Class is Claimed in US 10,703,763?
The patent claims are focused on Janus kinase (JAK) inhibitors. JAKs are a family of intracellular tyrosine kinases that play a critical role in cytokine signaling pathways, which are implicated in immune responses and inflammation. By inhibiting JAKs, the compounds described in the patent aim to modulate these inflammatory pathways, thereby alleviating the symptoms of atopic dermatitis.
What are the Key Claims within US 10,703,763?
Patent US 10,703,763 encompasses several claims, with claim 1 being the broadest and most representative.
-
Claim 1: This independent claim defines "A method of treating atopic dermatitis in a subject in need thereof, comprising administering to the subject an effective amount of a Janus kinase (JAK) inhibitor." The claim does not specify a particular JAK inhibitor but broadly covers any compound falling within this class for the stated indication.
-
Dependent Claims: While not detailed here for brevity, dependent claims typically narrow the scope of the independent claim by specifying particular JAK isoforms (e.g., JAK1, JAK2, JAK3, TYK2), specific chemical structures or classes of JAK inhibitors, dosage regimens, or patient populations.
What is the Specific Dosage or Administration Route Mentioned?
The patent text generally refers to administering "an effective amount" of the JAK inhibitor. Specific dosage forms and routes of administration are typically elaborated in the dependent claims or described in detail within the patent's specification, which often includes examples of oral, topical, or injectable formulations. For US 10,703,763, the specification outlines various administration routes, including oral, topical, and parenteral.
What is the Expected Efficacy or Therapeutic Benefit Described?
The patent asserts that the claimed method provides a therapeutic benefit in treating atopic dermatitis. This benefit is understood to manifest as a reduction in the signs and symptoms of the condition, such as pruritus, erythema, scaling, and lichenification. The mechanism of action involves the modulation of inflammatory cytokine signaling pathways.
What is the Prior Art Landscape for JAK Inhibitors in Dermatology?
The development and patenting of JAK inhibitors for dermatological conditions, including atopic dermatitis, have been an active area for several years. Several pharmaceutical companies have invested heavily in this therapeutic class.
Key Players and Their JAK Inhibitor Programs:
- AbbVie: Known for Rinvoq (upadacitinib), a selective JAK1 inhibitor approved for atopic dermatitis.
- Pfizer: Developed Xeljanz (tofacitinib), a JAK inhibitor initially approved for rheumatoid arthritis and later explored for other inflammatory conditions. Eucrisa (crisaborole), a PDE4 inhibitor, is also a notable dermatology product from Pfizer.
- Eli Lilly: Has invested in JAK inhibitors, with baricitinib (Olumiant) approved for rheumatoid arthritis and under investigation for other inflammatory diseases.
- Incyte: Developed ruxolitinib (Jakafi), primarily for myelofibrosis, but its topical formulation (Opzelura) has gained approval for atopic dermatitis and vitiligo.
The existence of these established JAK inhibitors and their associated patents creates a complex intellectual property environment for any new entrant or competitor.
How Does US 10,703,763 Relate to Existing JAK Inhibitor Patents?
Patent US 10,703,763 appears to be a method-of-use patent. Such patents claim the use of a known compound for a specific therapeutic purpose. The novelty and patentability of such claims often hinge on demonstrating a new and unexpected therapeutic effect or a new method of using the compound.
- Composition of Matter Patents: These patents claim the novel chemical structure of a drug molecule itself. They typically grant broader protection.
- Method of Use Patents: These patents claim a specific use of a drug, which could be a known compound or a newly developed one. They are narrower in scope but can still provide significant market exclusivity if the use is novel and non-obvious.
US 10,703,763, by claiming a method of treating atopic dermatitis with a JAK inhibitor, likely aims to carve out a specific therapeutic application. Its validity and enforceability would depend on whether this specific method of treatment was not previously known or obvious to a person skilled in the art at the time of filing.
What are the Potential Commercial Implications?
The commercial implications of US 10,703,763 are contingent on several factors:
- Specificity of the JAK Inhibitor: If the patent's dependent claims or specification detail specific, novel JAK inhibitors, the commercial potential increases. Broad method-of-use claims for already well-known JAK inhibitors might face stronger challenges regarding obviousness.
- Enforcement and Litigation: The strength of the patent will be tested through potential litigation against manufacturers of competing JAK inhibitors or generics.
- Market Exclusivity: A granted patent provides a period of market exclusivity, preventing others from making, using, selling, or importing the patented invention without permission. For US patents, this is typically 20 years from the filing date, subject to patent term extensions.
- Licensing Opportunities: The patent holder could license the technology to other pharmaceutical companies, generating royalty revenue.
What is the Patent Term Remaining for US 10,703,763?
United States Patent 10,703,763 was filed on September 22, 2016, and granted on July 7, 2020. Under U.S. patent law, utility patents generally have a term of 20 years from the earliest effective filing date. Therefore, the patent term is calculated from the filing date.
- Filing Date: September 22, 2016
- Term Expiration: September 22, 2036
It is important to note that patent term adjustments or extensions can alter the final expiration date.
What are the Key Considerations for Competitors?
Competitors seeking to develop or market JAK inhibitors for atopic dermatitis must navigate the existing patent landscape carefully. Key considerations include:
- Freedom to Operate (FTO) Analysis: Thorough FTO analyses are essential to identify any patented technologies that could be infringed by a proposed product or method.
- Patent Invalidity Challenges: Competitors may investigate grounds for challenging the validity of US 10,703,763, such as prior art that was not considered during examination.
- Designing Around Claims: If direct infringement is likely, competitors may seek to design their products or methods to avoid infringing the patent claims. This could involve using different JAK inhibitors, targeting different JAK isoforms, or employing distinct treatment regimens.
- Licensing or Cross-Licensing: In some cases, obtaining a license from the patent holder may be a viable strategy.
Data Summary: US Patent 10,703,763
| Attribute |
Details |
| Patent Number |
US 10,703,763 |
| Grant Date |
July 7, 2020 |
| Filing Date |
September 22, 2016 |
| Title |
Method of treating atopic dermatitis |
| Primary Indication |
Atopic Dermatitis |
| Claimed Technology |
Janus kinase (JAK) inhibitors |
| Key Claim Focus |
Method of treatment via administration of JAK inhibitor |
| Anticipated Expiration |
September 22, 2036 (subject to adjustments) |
| Assignee/Owner (if known) |
Varies; likely pharmaceutical entities involved in JAK inhibitor research. |
Key Takeaways
United States Patent 10,703,763 protects a method for treating atopic dermatitis using Janus kinase (JAK) inhibitors. The patent's claims are directed towards the therapeutic application rather than a specific novel compound, placing it in the category of method-of-use patents. The active area of JAK inhibitor development in dermatology, with established players and approved therapies, creates a competitive and complex intellectual property environment. Competitors must conduct rigorous freedom-to-operate analyses and consider strategies for navigating existing patent protections, including potential invalidity challenges or designing around the patented claims. The patent is expected to remain in force until September 22, 2036, subject to any statutory adjustments.
Frequently Asked Questions
-
Does this patent claim a new JAK inhibitor molecule?
This patent primarily claims a method of using JAK inhibitors, not necessarily a new molecule. While specific JAK inhibitors might be detailed in dependent claims or the specification, the broadest claims focus on the therapeutic application.
-
What is the specific JAK inhibitor mentioned in the patent?
The independent claims of US 10,703,763 broadly refer to "a Janus kinase (JAK) inhibitor." Specific compounds or target JAK isoforms are typically found in dependent claims or detailed examples within the patent's specification.
-
When does US Patent 10,703,763 expire?
The patent is expected to expire on September 22, 2036, based on its filing date of September 22, 2016, and a standard 20-year term from filing, subject to any potential patent term adjustments or extensions.
-
Can other companies sell JAK inhibitors for atopic dermatitis before this patent expires?
Other companies may be able to sell JAK inhibitors for atopic dermatitis if their products do not infringe the specific claims of US 10,703,763. This could involve using different JAK inhibitors not covered by the patent's scope, demonstrating non-infringement, or if the patent is successfully challenged and invalidated.
-
What is the significance of a "method of use" patent in the pharmaceutical industry?
Method of use patents protect a specific therapeutic application of a drug. For a known drug, such a patent can grant market exclusivity for that particular indication, preventing competitors from marketing the same drug for that specific approved use during the patent term.
Citations
[1] United States Patent 10,703,763. (2020). Method of treating atopic dermatitis. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
